<DOC>
	<DOCNO>NCT00090077</DOCNO>
	<brief_summary>To investigate safety , tolerability antiviral activity Non-nucleoside reverse transcriptase inhibitor ( NNRTI ) -experienced HIV-1 infect patient</brief_summary>
	<brief_title>Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : CD4 cell count great equal 200 cells/mm3 . HIV1 RNA &gt; 2000 copies/mL . Must history NNRTI treatment subsequent failure document evidence NNRTIassociated mutation phenotype display reduce activity efavirenz , nevirapine delavirdine . Normal rest 12lead electrocardiogram . Exclusion criterion : Any history seizure , CNS toxoplasmosis infection , CNS ( central nervous system ) lesion . Chronic diarrhea ( &gt; 3 loose stools/day ) . An active CDC Category C disease ( 1993 ) , except cutaneous Kaposi 's Sarcoma ( KS ) require systemic therapy trial . Less 4 week since stop antiretroviral therapy ( ART ) therapy prior Day 1 . Any acute laboratory abnormality . Positive HCV antibody HepBsAG . Active infection require therapy previous 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>GW695634G</keyword>
	<keyword>GW695634X</keyword>
	<keyword>GW678248X</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>NNRTI</keyword>
	<keyword>HIV</keyword>
</DOC>